Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines

Stefana Pecher, Beth Pflug, Alisa K W Brink, Joel B. Nelson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND. Some men treated with atrasentan (ABT-627), an endothelin A (ETA) receptor inhibitor, had declines in their serum PSA levels. It is our hypothesis that this decrease is due to anti-tumoral activity and not a reduction in PSA secretion at the cellular level. METHODS. Two PSA secreting prostate cancer cell lines (LAPC4 and LNCaP) were treated with atrasentan and an ETB receptor antagonist (A192621) in varying concentrations (10 -6-10-10 M) and PSA levels were measured in the culture media. RESULTS. LNCaP and LAPC4 cells both express ETA receptors. Neither the ETA or ETB antagonist altered PSA secretion, while addition of DHT, a positive control, produced a marked increase in PSA secretion. CONCLUSIONS. Blockade of the ETA receptor does not affect the secretion of PSA in prostate cancer cell lines.

Original languageEnglish (US)
Pages (from-to)175-177
Number of pages3
JournalProstate
Volume60
Issue number3
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Fingerprint

Endothelin A Receptors
Prostatic Neoplasms
Cell Line
A 192621
Endothelins
Culture Media
Serum
atrasentan

Keywords

  • Atrasentan
  • Endothelin receptor
  • Endothelin-1
  • Prostate cancer
  • PSA

ASJC Scopus subject areas

  • Urology

Cite this

Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines. / Pecher, Stefana; Pflug, Beth; Brink, Alisa K W; Nelson, Joel B.

In: Prostate, Vol. 60, No. 3, 01.08.2004, p. 175-177.

Research output: Contribution to journalArticle

Pecher, Stefana ; Pflug, Beth ; Brink, Alisa K W ; Nelson, Joel B. / Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines. In: Prostate. 2004 ; Vol. 60, No. 3. pp. 175-177.
@article{7c241d49ac9148eb970236da2487de07,
title = "Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines",
abstract = "BACKGROUND. Some men treated with atrasentan (ABT-627), an endothelin A (ETA) receptor inhibitor, had declines in their serum PSA levels. It is our hypothesis that this decrease is due to anti-tumoral activity and not a reduction in PSA secretion at the cellular level. METHODS. Two PSA secreting prostate cancer cell lines (LAPC4 and LNCaP) were treated with atrasentan and an ETB receptor antagonist (A192621) in varying concentrations (10 -6-10-10 M) and PSA levels were measured in the culture media. RESULTS. LNCaP and LAPC4 cells both express ETA receptors. Neither the ETA or ETB antagonist altered PSA secretion, while addition of DHT, a positive control, produced a marked increase in PSA secretion. CONCLUSIONS. Blockade of the ETA receptor does not affect the secretion of PSA in prostate cancer cell lines.",
keywords = "Atrasentan, Endothelin receptor, Endothelin-1, Prostate cancer, PSA",
author = "Stefana Pecher and Beth Pflug and Brink, {Alisa K W} and Nelson, {Joel B.}",
year = "2004",
month = "8",
day = "1",
doi = "10.1002/pros.20116",
language = "English (US)",
volume = "60",
pages = "175--177",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines

AU - Pecher, Stefana

AU - Pflug, Beth

AU - Brink, Alisa K W

AU - Nelson, Joel B.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - BACKGROUND. Some men treated with atrasentan (ABT-627), an endothelin A (ETA) receptor inhibitor, had declines in their serum PSA levels. It is our hypothesis that this decrease is due to anti-tumoral activity and not a reduction in PSA secretion at the cellular level. METHODS. Two PSA secreting prostate cancer cell lines (LAPC4 and LNCaP) were treated with atrasentan and an ETB receptor antagonist (A192621) in varying concentrations (10 -6-10-10 M) and PSA levels were measured in the culture media. RESULTS. LNCaP and LAPC4 cells both express ETA receptors. Neither the ETA or ETB antagonist altered PSA secretion, while addition of DHT, a positive control, produced a marked increase in PSA secretion. CONCLUSIONS. Blockade of the ETA receptor does not affect the secretion of PSA in prostate cancer cell lines.

AB - BACKGROUND. Some men treated with atrasentan (ABT-627), an endothelin A (ETA) receptor inhibitor, had declines in their serum PSA levels. It is our hypothesis that this decrease is due to anti-tumoral activity and not a reduction in PSA secretion at the cellular level. METHODS. Two PSA secreting prostate cancer cell lines (LAPC4 and LNCaP) were treated with atrasentan and an ETB receptor antagonist (A192621) in varying concentrations (10 -6-10-10 M) and PSA levels were measured in the culture media. RESULTS. LNCaP and LAPC4 cells both express ETA receptors. Neither the ETA or ETB antagonist altered PSA secretion, while addition of DHT, a positive control, produced a marked increase in PSA secretion. CONCLUSIONS. Blockade of the ETA receptor does not affect the secretion of PSA in prostate cancer cell lines.

KW - Atrasentan

KW - Endothelin receptor

KW - Endothelin-1

KW - Prostate cancer

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=3242768536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242768536&partnerID=8YFLogxK

U2 - 10.1002/pros.20116

DO - 10.1002/pros.20116

M3 - Article

C2 - 15176046

AN - SCOPUS:3242768536

VL - 60

SP - 175

EP - 177

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 3

ER -